Harlan M. Krumholz, MD, SM

All posts by Harlan M. Krumholz, MD, SM

May 1st, 2015

A Message from the Editor-in-Chief

Harlan Krumholz reflects on the CardioExchange community.

April 20th, 2015

Remembering Kanu Chatterjee

Harlan Krumholz shares memories of his mentor, legendary cardiologist and teacher Kanu Chatterjee.

February 23rd, 2015

Want to Blog for CardioExchange at ACC.15?


CardioExchange is looking for members to blog at ACC.15 next month in San Diego.

February 12th, 2015

Discontinuing Aspirin for Primary Prevention: What Do You Say to Your Patient?

In this scenario based on a study that found once-daily, low-dose aspirin did not significantly reduce the risk for CV events among older patients with atherosclerotic risk factors, Harlan Krumholz asks, “What do you say to your patient?”

January 21st, 2015

A Tragic Loss

The news of the death of Michael Davidson, a surgeon at Brigham and Women’s Hospital, allegedly at the hands of a patient’s relative, has shaken us all. The words of Betsy Nabel, on behalf of BWH, conveyed how much he was respected and loved. To his family, friends and colleagues, we send our sympathy. As […]

January 9th, 2015

Top 10 CardioExchange Posts from 2014


The most popular stories from 2014.

October 27th, 2014

Traditional CVD Risk Factors Mediate Between Lifestyle Factors and Cardiovascular Risk in Women

Nina Paynter discusses her case-cohort study comparing lifestyle-based with traditional cardiovascular disease prediction among women in the Women’s Health Initiative Observational Study.

October 23rd, 2014

The Survival Benefits of Physical Activity: Moderate vs. Vigorous Intensity

Eric Shiroma discusses his research group’s study of the relative survival benefits of moderate- versus vigorous-intensity physical activity.

October 20th, 2014

Are Women Who Live Near Roadways at Greater Risk for Sudden Cardiac Death?


Jaime E. Hart discusses her study of the relation between residential proximity to roadways and sudden cardiac death in women.

October 7th, 2014

Another Reason for Open Access to Clinical Trial Data?

A correction to the RE-LY trial results, partly brought to light because of litigation, has Harlan Krumholz wondering if this is another example of why we should have open access to clinical trial data.